Type 2 diadetes is associated with an increased risk of fractures. Calcium supplements are still in the middle of a cardiovascular controversy. Swiss recommandations are available for vitamin D supplementation. Zoledronate exerts a long-term remaining effect on bone resorption. After 5 years treatment with denosumab, fracture incidence remains low. Atypical femoral fractures associated with bisphosphonates treatment have been evaluated in the university hospital of Geneva.